Experiment 585589
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | WILLIAMSON,SK: WOLF,MK: EISENBERGER,MA: O'ROURKE,M: BRANNON,W: CRAWFORD,ED:. (1995). PHASE II EVALUATION OF DIDEMNIN B IN HORMONALLY REFRACTORY METASTATIC PROSTATE CANCER.. 13(2) |
| Amount utilized | |
| Compound isolated | |
| Disease | DIDEMNIN B WAS EVALUATED IN A PHASE II TRIAL IN THE TREATMENT OF METASTATIC, HORMONALLY REFRACTORY ADENOCARCINOMA OF THE PROSTATE. THIRTEEN PATIENTS WERE TREATED WITH DIDEMNIN B AT 3.5 MG/M2 AND 20 PATIENTS WERE TREATED AT 6.3 MG/M3 I.V. EVERY 28 DASY. RESPONSE WAS ASSESSED EVERY 8 WK. OF 32 EVALUABLE PATIENTS THERE WAS ONE PARTIAL RESPONSE FOR AN OVERALL RESPONSE RATE OF 3% (95% CONFIDENCE INTERVAL OF 0.1-16%). THE MOST COMMON TOXICITIES WERE NAUSEA, VOMITING, AND DIARRHEA. SERIOUS CARDIAC AND PULMONARY TOXICITIES WERE ALSO NOTED. THIS DRUG DOES NOT APPEAR TO WARRANT FURHTER EVALUATION IN THIS DISEASE AS A SINGLE AGENT. |
| Dose amount | 3.5 MG |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M |
| Dose expression | DOSE |